Table 2.
Spleen lymphocyte populations in the different mice groups (%)
| Mice | CD3+ | CD4+ | CD8+ | CD3+CD4+CD25+FoxP3+a | CD3−CD19+ | CD3−CD49+ | CD3+CD49+ |
|---|---|---|---|---|---|---|---|
| Non-tumor injected | 31.5 ± 4.5 | 9.1 ± 2.4 | 22.4 ± 3.1 | 6.1 ± 1.8 | 50.7 ± 4.5 | 8.3 ± 1.0 | 2.5 ± 1.1 |
| A7 Control | 25.3 ± 6.9* | 4.9 ± 1.7* | 20.4 ± 5.3 | 10.8 ± 4.2* | 54.6 ± 5.9 | 3.4 ± 2.0* | 0.9 ± 0.5* |
| A7 CpG | 40.9 ± 5.4** | 12.4 ± 2.2** | 28.5 ± 3.9** | 4.7 ± 3.8** | 43.6 ± 12.3 | 3.4 ± 1.3 | 2.0 ± 0.8** |
| A7 PSK | 51.6 ± 17.7** | 12.2 ± 2.4** | 39.4 ± 15.3** | 9.5 ± 3.8 | 27.4 ± 15.7** | 9.9 ± 0.6** | 1.6 ± 0.1** |
| A7 PSK + docetaxel | 32.2 ± 2.9** | 5.7 ± 0.8 | 26.5 ± 2.2** | 1.1 ± 0.3** | 52.9 ± 5.3 | 2.7 ± 0.1 | 0.9 ± 0.1 |
Data are expressed as mean ± SD of 10 mice of each group
* P < 0.05 when A7 control group was compared to non-tumor-injected group
** P < 0.05 when each treatment group was compared to A7 control group
aPercentage among CD4+ cells